GLUTAMINE

/static/temp/default.svg

Search structure


Synonyms	Endari FEMA NO. 3684 Glutamine L-glutamine Levoglutamide NSC-27421 Nutrestore
Status
Molecule Category	UNKNOWN
ATC	A16AA03
UNII	0RH81L854J
EPA CompTox	DTXSID1023100


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ZDXPYRJPNDTMRX-VKHMYHEASA-N
Smiles	NC(=O)CC[C@H](N)C(=O)O
InChI	InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H10N2O3
Molecular Weight	146.15
AlogP	-1.34
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	4.0
Polar Surface Area	106.41
Molecular species	ZWITTERION
Aromatic Rings	0.0
Heavy Atoms	10.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of ASCT2 mediated [3H]-D-serine uptake in rat hippocampal astrocytes at 1 mM after 5 mins by beta counting analysis	Rattus norvegicus	25.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	0.94 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	-11.54 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.1 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.1 %

Cross References

Resources	Reference
ChEBI	58359
ChEMBL	CHEMBL930
DrugBank	DB00130
DrugCentral	1311
FDA SRS	0RH81L854J
Human Metabolome Database	HMDB0000641
Guide to Pharmacology	4634
KEGG	C00064
PDB	GLN
PharmGKB	PA10090
PubChem	5961
SureChEMBL	SCHEMBL7453
ZINC	ZINC000001532526

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).